Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending December 31, 2021
November 11, 2021 at 11:30 pm EST
Share
Otsuka Holdings Co., Ltd. revised earnings guidance for the fiscal year ending December 31, 2021. For the period, the company expected revenue of JPY 1,480,000 million, operating profit of JPY 203,000 million, profit for the period of JPY 165,000 million and basic earnings per share of JPY 296.84 against previous guidance revenue of JPY 1,480,000 million, operating profit of JPY 208,000 million, profit for the period of JPY 169,000 million and basic earnings per share of JPY 304.21.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
